Detail of "5661-03-0"

Reference

Interaction between substituted chloramines and liquid ammonia using the indirect Raschig process

All Rights Reserved. Interaction between substituted chloramines and liquid ammonia using the indirect Raschig process. Stephan, Juliette; Berthet, Jacques; Goutelle, Veronique; Pasquet, Veronique; Delalu, Henri (Laboratoire Hydrazines et Procedes, CNRS UMR 5179, Universite Claude Bernard LYON 1, ISOCHEM, Villeurbanne 69622, Fr.). Journal of Chemical Research, (12), 808-812 (English) 2005 Science Reviews. CODEN: JCROA4. DOCUMENT TYPE: Journal CA Section: 21 (General Organic Chemistry) Section cross-reference(s): 22 Various hydrazines R1R2NNH2 [R1 = R2 = Me; R1R2N = 1-piperidinyl, 3,4-diazabicyclo[4.In this article, certain chemicals are used. Some of their cas registry numbers are 124-40-3 and 5661-03-0 3.0]non-2-yl] were synthesized by the indirect Raschig process, which consists of introducing a substituted chloramine R1R2NCl into liq. ammonia under pressure. The exptl. results, in disagreement with those reported in the literature, allowed to propose a new mechanistic scheme involving a chlorine transfer reaction, which provides chloramine NH2Cl and the corresponding amine R1R2NH as first intermediates. Next, chloramine reacts immediately with the substituted amine in agreement with the direct Raschig process to produce the hydrazine. Under these conditions, the nature of the hydrazine is kinetically controlled by the excess amine. It is then possible to synthesize different hydrazines from the same substituted chloramine. .

Preparation of octahydropentalene-substituted pyrazoline derivatives as cannabinoid receptor modulators

All Rights Reserved. Preparation of octahydropentalene-substituted pyrazoline derivatives as cannabinoid receptor modulators. Torrens Jover, Antonio; Yenes Minguez, Susana (Laboratorios del Dr. Esteve, S. A., Spain). PCT Int. Appl. WO 2007009711 A2 25 Jan 2007, 93pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: C07D. APPLICATION: WO 2006-EP6985 16 Jul 2006. PRIORITY: EP 2005-384018 15 Jul 2005; US 2005-705433P 5 Aug 2005; EP 2006-8579 26 Apr 2006. DOCUMENT TYPE: Patent CA Section: 28 (Heterocyclic Compounds (More Than One Hetero Atom)) Section cross-reference(s): 1, 63 The title compds. I [X, Y = (un)substituted Ph, thienyl, naphthyl or pyridyl; R8 = H or alkyl while R9 = II (wherein R5 = R7 = H, halo, OH, etc.Several substances like 919489-86-4 may be metioned in this study.); or NR8R9 = III], useful for the prepn. of a medicaments for the treatment of humans and animals, were prepd. General procedure for prepn. of compds. I is described. Twenty-eight compds. I such as IV were prepd. Selected compds. I were tested for their cannabinoid activity in-vivo (data given). The present invention also relates to methods for prepn. of compds. I and medicaments comprising compds. I. .